Company intelligence / Profile preview

CellMed

Ownership: Private
Development stage: Preclinical

Overview

2,500+ member pharmacies in Korea as of Feb.2024, US market entry with Atlanta pharmacy in July.2023, Patent portfolio covering anti-aging and oncology formulations since.2018

Therapeutic areas: OtherNeurologyRheumatology
Modalities: Natural compoundsStem cell therapy (via Cellmed Life)Micro-implants (via CellMed Germany)
Industry: Biotech

Drug pipeline

7 assets

GLP-1 CellBeads

6 more assets in the full pipeline.

Request access →

Partnerships

Seoul Pharmacist AssociationGyeongnam Changwon Pharm Expo organizers

Beyond the preview

Go deeper on CellMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellMed.

Explore the full profile